By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Winterthurerstr. 190

Zurich    CH-8057  Switzerland
Phone: 41-1-635-3159 Fax: +41-1-635 2001



Company News
OctoPlus Expands Development Agreement With ESBATech on Controlled Release Product for Ophthalmic Indications 2/24/2011 8:19:03 AM
Alcon Laboratories, Inc. (ACL) to Acquire Swiss Biotechnology Firm, ESBATech for $589 Million 9/14/2009 7:05:15 AM
ESBATech: Topical ESBA105 Demonstrates Efficacy in the Back of the Eye to Inhibit Neovascularization 3/24/2009 10:57:57 AM
ESBATech's Antibody Fragment ESBA105 Enters Phase IIa in Uveitis Study 2/24/2009 10:48:39 AM
ESBATech's Antibody Fragment Enters Phase Ib/IIa in Ophthalmology 2/3/2009 10:42:52 AM
ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity 1/9/2009 7:59:57 AM
ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications Preclinical Pharmacokinetic Data to be Presented at the 7th International Symposium on Uveitis in Germany 9/8/2008 9:47:13 AM
ESBATech Raises Additional $22M, Extending Series B Venture Financing Positive Results to Date Drive Decision to Expand its Proprietary Therapeutic Pipeline 8/7/2008 6:36:18 AM
ESBATech's Lead Antibody Fragment Enters Clinical Development for Ophthalmic Indications 4/24/2008 7:40:21 AM
ESBATech's Antibody Fragments Demonstrate Penetration into the Eye with Topical Delivery via Eye Drops 2/25/2008 8:10:59 AM